Articles
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.
- Journal/Conference:
- Pharmacoecon Open
- Author(s):
- Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, Cooney P, Blanchette F, Patel BP, Grima D.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Multiple Sclerosis, Nervous System
“Economic analysis of n-butyl cyanoacrylate compared with ethylene vinyl alcohol copolymer liquid embolic embolization of brain arteriovenous malformations (bAVMs) from a US hospital perspective”
- Journal/Conference:
- Interventional Neuroradiology
- Author(s):
- Sudhakar R. Satti , Emilie Kottenmeier, Alia Khaled, George W.J. Wright and Heather L. Cameron
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Brain
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
- Journal/Conference:
- Americal Journal of Cardiovascular Drugs
- Author(s):
- Rozenbaum, M.H.; Tran, D.; Bhambri, R.; Nativi-Nicolau, J.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Cardiovascular
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
- Journal/Conference:
- BMC Health Services Research Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, et al. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. BMC Health Serv Res. 2022 Jul 14;22(1):916. doi: 10.1186/s12913-022-08274-x https://pubmed.ncbi.nlm.nih.gov/35836170/
- Author(s):
- Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, Drea E, Vogelzang NJ An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective Oncology BMC Health Services Research Morgans AK, Hutson T, Guan AKD, Garcia D, Zhou A, et al. An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. BMC Health Serv Res. 2022 Jul 14;22(1):916. doi: 10.1186/s12913-022-08274-x https://pubmed.ncbi.nlm.nih.gov/35836170/
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Oncology
Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review
- Journal/Conference:
- ASH 2022
- Author(s):
- Fonseca, R.; Tran, D.; Rosta, E.; Laidlaw, A.; Rai, M.; Duran, J.; Ammann, E.M.
- Publication Date:
- 2022
- Topic/Therapeutic Area:
- Blood, Oncology
What challenges do pharma companies face that risk limiting their ability to capitalize on this unique opportunity?
Companies are limited in the opportunities to in-licensing more clinical and commercially viable assets due to commercial capacity and capability constraints. However, by not exploring in-licensing opportunities, large pharma is missing out on opportunities for meaningful…
Overcome In-Licensing Challenges with EVERSANA
Increasing the throughput of commercialized in-licensed assets can have a multi-billion-dollar impact on valuations and create significant funding pools for further pipeline and business development initiatives. EVERSANA’s in-licensing capabilities were designed to eliminate the capacity and…
In-Licensing – A Once-in-a-Lifetime Moment of Market Conditions
Faruk Abdullah, General Manager, Advisory Services shares insights on the once-in-a-lifetime moment of market macro dynamics, making in-licensing opportunities. The opportunity at hand for large pharma has been created by the once-in-a-lifetime, current market dynamics. These…
Why is in-licensing such an important growth lever for companies?
In-licensing is a significant growth lever for a variety of reasons, including: Serving as a risk mitigation tool Reinforce a company’s therapeutic area footprint Serving as a growth catalyst channel to further diversify your pipeline and…